TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2
Gongwei Wu(Harvard University), David M. Weinstock(Broad Institute), M. Jones(Harvard University), Wing C. Chan(Ontario Institute for Cancer Research), Jihe Liu(Harvard University), Abner Louissaint(Massachusetts General Hospital), Myles Brown(Harvard University), Lu Yang(City Of Hope National Medical Center), Renee Chen(National Institutes of Health), Tayla B. Heavican‐Foral(Dana-Farber Cancer Institute), Huiyun Liu(University College London), Matthew Meyerson(Broad Institute), Geoffrey M. Nelson(MRC Laboratory of Molecular Biology), Wenchao Wu(State Key Laboratory of Oncology in South China), Kristen L. Jones(Oregon Health & Science University), Lydie Debaize(Harvard University), Karen Adelman(National Institutes of Health), Ajit J. Nirmal(Brigham and Women's Hospital), Salvia Jain(Broad Institute), chun-Wei David Chen(City of Hope), Andrew L. Feldman(Mayo Clinic in Arizona), Xiaoyang Zhang(University of Utah), Ran Xu(Harvard University), Kristen E. Stevenson(Dana-Farber Cancer Institute), Shannan Ho Sui, Catharine Leahy(Harvard University), Samuel Y. Ng(National Cancer Institute), Noriaki Yoshida(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k